<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096601</url>
  </required_header>
  <id_info>
    <org_study_id>ND0612/004</org_study_id>
    <nct_id>NCT02096601</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients</brief_title>
  <official_title>A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label phase I/IIa study to evaluate the safety and tolerability of 6 different doses/
      infusion rates of subcutaneous (SC) ND0612 solution in PD patients; to determine if
      continuous delivery of levodopa and carbidopa can provide reduced variability in plasma
      concentration; to test and compare the PK profile of high and low concentrations of CD; to
      assess preliminary efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events frequency</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>LD, CD and 3-OMD PK analysis from sample taken on Days 3, 4 and 5 will be used to determine the Fluctuation Index, its CV, AUC, Cmin, Cmax, and tmax.</measure>
    <time_frame>Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability: Number of patients who discontinued due to adverse events</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>ND0612</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levodopa and carbidopa SC solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral levodopa and carbidopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral levodopa and carbidopa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa and carbidopa SC solution</intervention_name>
    <description>Levodopa and carbidopa SC solution</description>
    <arm_group_label>ND0612</arm_group_label>
    <other_name>ND0612</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral levodopa and carbidopa</intervention_name>
    <description>Oral levodopa and carbidopa</description>
    <arm_group_label>Oral levodopa and carbidopa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female PD patients of any race aged 30 to 80 years

          2. PD diagnosis consistent with the UK PD Society Brain Bank criteria.

          3. Stable doses of anti PD drugs for at least 30 days

          4. PD patients with well-defined morning &quot;OFF&quot; and a good response to LD

          5. MMSE score &gt; 26

          6. No clinically significant medical, psychiatric or laboratory abnormalities

        Exclusion Criteria:

          1. Atypical or secondary Parkinsonism.

          2. Acute psychosis or hallucinations.

          3. Subjects treated with neuroleptics

          4. History of melanoma or significant skin disorders.

          5. Prior neurosurgical procedure for PD.

          6. Patients with a history of drug abuse or alcoholism

          7. Clinically significant ECG abnormalities.

          8. Renal or liver dysfunction

          9. Subjects who have participated in another clinical study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Motor fluctuations</keyword>
  <keyword>levodopa pharmacokinetics</keyword>
  <keyword>levodopa and carbidopa solution</keyword>
  <keyword>continuous subcutaneous delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

